Obiettivo Destruction of particular cartilage occurs in rheumatoid arthritis (RA) and osteoarthritis (OA) having an incidence of 1 % and 12% in the population respectively. The resulting disabilities of RA and OA have a major impact on the European economy and health. The novel genetic therapies available have a serious limitation as only targets the inflammatory process, which returns when therapy ceases and does not cure-damaged cartilage. Our hypothesis is: Restoration of joint function could be achieved by long term therapy that is both anti-inflammatory and provides for cartilage differentiation factors that facilitate and induce tissue repair using genetically engineered mesenchymal stem cells (MSC). We will genetically engineer mouse and human MSC using transcription ally regulated lent viral vectors. These cells will attach to damaged cartilage and synthetic matrices, express chondrogenic differentiation or transcription factors and immunosuppressive compounds to enable long-term tissue repair in OA and RA. Engineered cells will be assessed in vitro and in vivo in models of RA and OA. This project will deliver new therapeutics in form of nucleic acids, proteins and engineered cells. These novel technologies would be exploited commercially. Campo scientifico natural sciencesbiological sciencesbiochemistrybiomoleculesnucleic acidsmedical and health sciencesclinical medicinerheumatologymedical and health sciencesmedical biotechnologygenetic engineeringgene therapynatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesmedical biotechnologycells technologiesstem cells Programma(i) FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002 Argomento(i) 1.1.1.-3. - Key action The "Cell factory" Invito a presentare proposte Data not available Meccanismo di finanziamento CSC - Cost-sharing contracts Coordinatore Queen Mary and Westfield College Contributo UE Nessun dato Indirizzo Mile End Road E1 4NS London Regno Unito Mostra sulla mappa Costo totale Nessun dato Partecipanti (6) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto GBF - NATIONAL CENTRE FOR BIOTECHNOLOGY Germania Contributo UE Nessun dato Indirizzo 1,Mascheroder Weg 1 38124 BRAUNSCHWEIG Mostra sulla mappa Costo totale Nessun dato GENETHON III Francia Contributo UE Nessun dato Indirizzo RUE DE L'INTERNATIONALE 1BIS 91002 EVRY Mostra sulla mappa Costo totale Nessun dato INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Francia Contributo UE Nessun dato Indirizzo Rue de Tolbiac, 101 75654 PARIS Mostra sulla mappa Costo totale Nessun dato ISTITUTO ORTOPEDICO RIZZOLI Italia Contributo UE Nessun dato Indirizzo Via di Barbiano, 1/10 40136 BOLOGNA Mostra sulla mappa Costo totale Nessun dato SWISS FEDERAL INSTITUTE OF TECHNOLOGY ZUERICH Svizzera Contributo UE Nessun dato Indirizzo 101,Raemistrasse 101, ETH Zentrum 8092 ZURICH Mostra sulla mappa Costo totale Nessun dato THE HEBREW UNIVERSITY OF JERUSALEM - THE AUTHORITY FOR RESEARCH AND DEVELOPMENT Israele Contributo UE Nessun dato Indirizzo Givat Ram Campus, Edmond Safra 91904 JERUSALEM Mostra sulla mappa Costo totale Nessun dato
